http://dx.doi.org/10.18081/2378-5225-016-06/56-64Electronic address: lee@ualberta.ca. ¹Department of Neurology, University of Alberta, Canada. ²Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, China. ³Department of neurology, Renmin Hospital of Wuhan University, Wuhan, Hubei
Abstract
Because there is no curative treatment for ischemic spinal cord (SCI), investigating animal model is highlight to assess therapies for patients suffering from SCI. Orciprenaline exert its effects through stimulation β adrenergic receptors of intracellular adenylyl cyclase, although the effects on angiogenesis remain unclear. The objective of this study is investigated protective effects of orciprenaline on SCI. Spinal cord ischemia was induced by aortic cross-clamp (infrarenal) for 15 min in mice model, and orciprenaline was intravenously administered once at the onset of reperfusion. Assessments all postoperative neurological function, Western blots for ERK/Akt, histopathology, malondialdehyde (MDA) levels activity in the spinal cord. We found orciprenaline efficiently increased spinal blood flow by activating angiogesis, and subsequently enhanced neuronal survival, and improved locomotor recovery. Moreover, administration of orciprenaline down-regulates MAPKs (ERK and Akt) signaling pathway. These data suggest that orciprenaline has protective effects on spinal cord injury, indicating a potential clinical application.
Keywords: Spinal cord injury; MAPKs; Orciprenaline; ERK/Akt
Full-Text/PDF
